A Phase 1, Single-Center Study Evaluating the Safety and Tolerability of RCT2100 in Healthy Participants

Conditions: Cystic Fibrosis Interventions: Drug: RCT2100; Other: Placebo Sponsors: ReCode Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials